N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

Inclusion Criteria:

• Patients admitted to the ICU
• Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion

Exclusion Criteria:

• Age lower than 18 years old
• Chronic renal failure
• A known history of allergy to any of the study drugs
• Using n-acetylcysteine to paracetamol overdose
• Pregnant women
• Patients who used iodinated contrast medium
• Hemoglobin less than 6.5 mg/dl
• Cancer patients